Meningeal melanocytoma

Summary

Meningeal melanocytoma (MONDO:0016746) is a disease and 4 clinical trials. Top therapeutic interventions include bevacizumab and edotreotide gallium ga-68. A subtype of central nervous system melanocytic neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	meningeal melanocytoma
Mondo ID	MONDO:0016746
Orphanet	252046
DOID	DOID:5900
NCIT	C4662
SNOMED CT	277527003
UMLS	C1266113
MedGen	226842
GARD	0020740
Is cancer (heuristic)	no

Also known as: leptomeningeal melanocytoma · melanocytoma of meninges · melanocytoma of the meninges · meninges melanocytoma

Disease family

This is a subtype of central nervous system melanocytic neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system melanocytic neoplasm › meningeal melanocytoma

Related subtypes (2): diffuse meningeal melanocytosis, primary melanoma of the central nervous system

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00492089	PHASE2	COMPLETED	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
NCT00110032	PHASE1	TERMINATED	Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
NCT02194452	Not specified	WITHDRAWN	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
NCT05984108	Not specified	UNKNOWN	Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
EDOTREOTIDE GALLIUM GA-68	4	1